Cargando…

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial

A global phase 3 study evaluated the pharmacokinetics, efficacy and safety of a recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in 27 previously treated male children (1–11 years) with severe and moderately severe haemophilia B (factor IX [FIX] activity ≤2 IU/dl). All...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kenet, Gili, Chambost, Hervé, Male, Christoph, Lambert, Thierry, Halimeh, Susan, Chernova, Tatiana, Mancuso, Maria Elisa, Curtin, Julie, Voigt, Christine, Li, Yanyan, Jacobs, Iris, Santagostino, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Schattauer 2016
Materias:	Coagulation and Fibrinolysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039316/ https://www.ncbi.nlm.nih.gov/pubmed/27583313 http://dx.doi.org/10.1160/TH16-03-0179

Ejemplares similares

Pharmacokinetics of Recombinant Human Soluble Thrombomodulin in Disseminated Intravascular Coagulation Patients with Acute Renal Dysfunction
por: Hayakawa, Mineji, et al.
Publicado: (2017)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays
por: Horn, C., et al.
Publicado: (2018)

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
por: von Mackensen, Sylvia, et al.
Publicado: (2018)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Polyphosphate Delays Fibrin Polymerisation and Alters the Mechanical Properties of the Fibrin Network
por: Whyte, Claire S., et al.
Publicado: (2016)

Impact of Fibrinogen Carbamylation on Fibrin Clot Formation and Stability
por: Binder, Veronika, et al.
Publicado: (2017)

Are Cardiovascular Risk Factors also Associated with the Incidence of Atrial Fibrillation?: A Systematic Review and Field Synopsis of 23 Factors in 32 Population-Based Cohorts of 20 Million Participants
por: Allan, Victoria, et al.
Publicado: (2017)

Platelet Turnover Predicts Outcome after Coronary Intervention
por: Freynhofer, Matthias K., et al.
Publicado: (2017)

Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic
por: Patel, Rachna, et al.
Publicado: (2021)

Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
por: Zollner, S, et al.
Publicado: (2014)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B
por: Gill, Joan C., et al.
Publicado: (2019)

Coagulation Dysfunction and Hematological Changes in 633 Patients with COVID-19
por: Yang, Mo, et al.
Publicado: (2020)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

THE EFFECT OF THE COVID-19 PANDEMIC PROCESS ON TREATMENT COMPLIANCE IN HEMOPHILIA PATIENTS
por: Şahin, Şifa, et al.
Publicado: (2022)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

Coagulation factor XII protease domain crystal structure
por: Pathak, M, et al.
Publicado: (2015)

Sirtilins – the new old members of the vitamin K‐dependent coagulation factor family
por: Dahms, Sven O., et al.
Publicado: (2019)

Study of Coagulopathies in Covid 19 Positive Patients & Their Correlation with Outcome of Disease
por: Khunger, Jitender, et al.
Publicado: (2020)

VWF/ADAMTS13 Ratios Are Potential Markers of Immunothrombotic Complications in Patients with COVID-19: A Cross-Sectional Study
por: Madeeva, Daria V, et al.
Publicado: (2020)

COVID-19 in Relation to Hematological Events (Thrombosis/Bleeding) and Mortality in Inpatient Setting
por: Gadde, Saikrishna, et al.
Publicado: (2020)

Plasma Exchange for COVID-19 Thrombo-Inflammatory Disease
por: Thomas, Mari, et al.
Publicado: (2020)

Venous Thromboembolic Disease in Children Associated with COVID-19
por: Narang, Shalu, et al.
Publicado: (2020)

Frequency of Venous Thromboembolism in 6513 Patients with COVID-19: A Retrospective Study
por: Crowther, Mark, et al.
Publicado: (2020)

Recombinant factor IX Fc for major surgery in hemophilia B: factor IX plasma activity levels and effective hemostasis
por: Shapiro, Amy D., et al.
Publicado: (2023)

Assessment of the protein interaction between coagulation factor XII and corn trypsin inhibitor by molecular docking and biochemical validation
por: Hamad, B. K., et al.
Publicado: (2017)

An engineered U1 small nuclear RNA rescues splicing-defective coagulation F7 gene expression in mice
por: Balestra, D, et al.
Publicado: (2014)

Plasma free fatty acid levels influence Zn(2+)-dependent histidine-rich glycoprotein–heparin interactions via an allosteric switch on serum albumin
por: Kassaar, O, et al.
Publicado: (2015)

Fibrinolysis in a lipid environment: modulation through release of free fatty acids
por: RÁBAI, G, et al.
Publicado: (2007)

Hindered dissolution of fibrin formed under mechanical stress
por: Varjú, I, et al.
Publicado: (2011)

Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis
por: Mutch, N J, et al.
Publicado: (2010)

Lytic and mechanical stability of clots composed of fibrin and blood vessel wall components
por: Rottenberger, Z, et al.
Publicado: (2013)

Leukemia‐associated Rho guanine‐nucleotide exchange factor is not critical for RhoA regulation, yet is important for platelet activation and thrombosis in mice
por: Williams, C. M., et al.
Publicado: (2015)

Increased urokinase and consumption of α(2)‐antiplasmin as an explanation for the loss of benefit of tranexamic acid after treatment delay
por: Longstaff, C., et al.
Publicado: (2018)

On the localization of the cleavage site in human alpha‐2‐antiplasmin, involved in the generation of the non‐plasminogen binding form
por: Abdul, Shiraazkhan, et al.
Publicado: (2020)

VhH anti‐thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow
por: van Moorsel, Marc V. A., et al.
Publicado: (2022)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
por: López‐Jaime, Francisco José, et al.
Publicado: (2023)

Modified Factor VIII and Factor IX recombinant products
por: Santagostino, Elena, et al.
Publicado: (2018)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_jrpg9d36t5scmmibapgfbmpfhb